Having two vaccines is good. But three is better — and could make a major difference in getting the pandemic under control.

“It could be a total game changer,” said Dr. Muriel Jean-Jacques, an assistant professor of medicine at Northwestern University.

Millions of doses of the Covid-19 vaccine developed by Johnson & Johnson will soon be available in the United States, a much-anticipated development that could help turn the tide of the pandemic by vastly speeding up the number of vaccinations given across the country.

Experts say the newly authorized vaccine could play a key role in staving off another surge of infections, particularly as the recent sharp declines in reported cases of Covid-19 appear to be leveling off and rising once again.

“We’ve never had to vaccinate our whole population at the same time before — not to mention the rest of the world — so having more vaccines will make that easier,” Jean-Jacques said.

The single-dose vaccine, manufactured by a Johnson & Johnson subsidiary called Janssen Biotech, received emergency use authorization from the FDA on Saturday. The company shipped out 4 million doses Monday, with another 16 million doses expected by the end of the month.

The vaccine’s authorization is a significant milestone, because it will help ease the supply and distribution bottlenecks that have hampered the rollout of Covid-19 vaccines across the country, said Dr. Stella Safo, an assistant professor of medicine at the Icahn School of Medicine at Mount Sinai and an HIV primary care physician.

March 1, 202110:27

“It’s invaluable,” she said. “The more options we have, the better. It’s really a thing to celebrate.”

The Johnson & Johnson vaccines do not require ultra-cold storage conditions, as the vaccines made by Moderna and Pfizer-BioNTech do, and can instead be kept in regular refrigerators. This could ease some distribution challenges, particularly for rural communities.

And the vaccine only requires a single dose, unlike the Moderna and Pfizer vaccines, which require two shots administered three to four weeks apart.

A single dose vaccine could help boost the country’s rate of vaccination, and increasing the number of people vaccinated each week will be critical for containing new outbreaks, especially as more contagious variants of the coronavirus become more widespread.

An FDA analysis found that the Johnson & Johnson vaccine was 85 percent effective at preventing severe Covid-19 and 100 percent effective in preventing death. In the U.S., the single dose was 72 percent effective at preventing moderate to severe disease.

Moderna’s vaccine is 94 percent effective at preventing symptomatic Covid-19, and Pfizer’s vaccine was found to be 95 percent effective. But experts said the three vaccines should not be compared based on those numbers alone, because they all provide strong protection against severe disease.

“All three of them are really quite good, and people should take the one that’s most available to them,” Fauci said Sunday on NBC’s “Meet the Press.”

The Johnson & Johnson clinical trials also took place later in the pandemic and in regions where worrisome variants of the coronavirus have emerged.

“We’re not comparing the same thing because the pandemic has changed,” Safo said. “The reality of where we are now is very different compared to the summer, when those other vaccines were first evaluated.”

Scientists have been particularly concerned about how well the vaccines currently available will protect against the different variants that are circulating and new ones that may emerge in the future.

In South Africa, where a strain of the virus thought to be more contagious is now widespread, the Johnson & Johnson vaccine was found to be 64 percent effective at preventing moderate to severe disease.

In early analyses, both the Moderna and Pfizer vaccines were found to be less protective against the South African variant, though neutralizing antibodies for both remained above protective levels.

Public health officials have said the U.S. is in a race against time to vaccinate as many people as possible before other variants begin spreading. Researchers are especially worried about the virus mutating in a way that enables it to escape the protection induced by vaccines, though there is no evidence to suggest that has happened yet.

“If we want to stem the pandemic, we need all hands on deck and all vaccines on deck,” said Paul Goepfert, a professor of medicine and microbiology at the University of Alabama at Birmingham, who was the lead investigator of a study on the Johnson & Johnson vaccine’s effectiveness.

Still, a third vaccine option now raises important questions about who should get which vaccine and why. While Johnson & Johnson’s vaccine may be more practical for certain communities, it’s important for public health officials to be mindful of how people are affected by these decisions, Jean-Jacques said.

“Perception is going to be key and trust is going to be key,” she said. “If the perception is that this is a second-class vaccine or that this vaccine is being reserved for historically marginalized communities, then that will put up more barriers for people getting the vaccine.”

One way to combat misperceptions is to avoid direct comparisons and instead stress the context behind the numbers.

“The message that this vaccine is 100 percent effective against death from Covid-19 is born out by the data,” Jean-Jacques said. “That’s a simple message to get across.”

Safo added that doctors and public health officials should also focus on what’s at stake, which is especially important when dealing with vaccine hesitancy.

“The thing we doctors can do is bring people back to the desired result,” she said, “which means focusing on things like: Will the vaccine prevent you from getting very sick from Covid? Will it prevent you from dying from Covid? And is this vaccine safe?”

Rather than exacerbating equality issues, Safo said she hopes the newly authorized Johnson & Johnson vaccine will prompt public health departments to re-evaluate vaccine distribution strategies to better reach at-risk or underserved communities.

“We have three options now,” she said, “so we should be smart about how we use them.”

CORRECTION (March 1, 7:15 p.m. ET): A previous version of this article misstated the number of doses of the Johnson & Johnson vaccine that are expected to ship by the end of the month in addition to the 4 million doses shipped Monday. It is 16 million doses, not 20 million.

Source: | This article originally belongs to Nbcnews.com

You May Also Like

Telluride Film Festival Goes On, Despite Anxiety Over Strikes

Majestic vistas, burbling brooks and sanguine festival goers are the hallmarks of…

Former AAMCO executive alleges racial pay discrimination and retaliation in lawsuit

A former Black executive at AAMCO’s corporate offices in Pennsylvania filed a…

Pivot from Paris: Submarine feud surfaces European anger as U.S. shifts focus to Asia

Thousands of miles away from the French fury, the recalled ambassadors and…

Fans still mourn Kobe Bryant’s sudden death one year later

Tony Starks of Accokeek, Maryland, remembers where he was one year ago…